As a patient safety management practice in outpatient cancer drug therapy at community pharmacies, continuous follow-up after the dispensing of medication is required. In 2013, QOL Pharmacy Kohoku and its affiliated stores started the "Telephone Follow-up for Cancer Patients" program, which utilizes telephones and information communication devices to communicate with patients and provide information to hospitals. Specifically, follow-up, including phone calls, is used to ascertain medication status and side effects before the next visit to the hospital, and feedback is provided to the prescribing source using trace reports. In some cases, this initiative has led to an early detection of side effects, reduction in the usage of anticancer drugs, and enhancement of supportive care, leading to patient safety and security. In addition, on August 1, 2021, a new pharmacy accreditation system was launched with two new functional categories, namely "Community Cooperative Pharmacies" and "Specialty Medical Institution Cooperative Pharmacies." Specialty medical institution-linked pharmacies are defined as pharmacies that can provide specialized and more advanced pharmacological management and dispensing of medications in cooperation with other pharmacies and medical institutions for patients who require specialized pharmacological management, such as in the case of cancer. Following our certification as a specialized medical institution collaborative pharmacy, we intend to continue the efforts we have invested to date and create a community that can assume a prevailing role in patient safety management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1248/yakushi.22-00160-4 | DOI Listing |
Curr Med Chem
January 2025
Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, 384012, India.
Aims: This study aimed to develop Imatinib Mesylate (IMT)-loaded Poly Lactic-co-Glycolic Acid (PLGA)-D-α-tocopheryl polyethylene glycol succinate (TPGS)- Polyethylene glycol (PEG) hybrid nanoparticles (CSLHNPs) with optimized physicochemical properties for targeted delivery to glioblastoma multiforme.
Background: Glioblastoma multiforme (GBM) is the most destructive type of brain tumor with several complications. Currently, most treatments for drug delivery for this disease face challenges due to the poor blood-brain barrier (BBB) and lack of site-specific delivery.
Expert Rev Clin Pharmacol
January 2025
Department of Internal Medicine, HIND Institute of Medical Sciences, Barabanki, India.
Introduction: Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials. We did this systematic review and meta-analysis to pool the results of all available trials and ascertain its safety and efficacy in the treatment of obesity.
Material And Methods: A literature search was conducted in PubMed, Cochrane Central and Embase using appropriate search terms and randomized control trials (RCTs) were identified which reported the safety and efficacy of retatrutide.
J Agromedicine
January 2025
Department of Fishery and New Biomarine Industry, SINTEF Ocean, Trondheim, Norway.
Objective: People working in the Norwegian fish farming industry work in a high energy environment, where there are many hazards in the daily work. An important part of mitigating hazardous situations is to keep track of the characteristics of the accidents that have already happened and to learn from these, when planning future work. The objective of this study was to strengthen the knowledge of factors and conditions influencing personnel safety in Norwegian fish farming, based on analyses of registered occupational fatalities and injuries.
View Article and Find Full Text PDFWorld J Diabetes
January 2025
Department of Anatomy, Division of Human Biology, School of Medicine, IMU University, Kuala Lumpur 57000, Malaysia.
Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), poses a significant global health challenge. Traditional management strategies primarily focus on glycemic control; however, there is a growing need for comprehensive approaches addressing the complex pathophysiology of diabetes complications. The recent study by Attia explores the potential of a novel therapy combining metformin with cholecalciferol (vitamin D3) and taurine to mitigate T2DM-related complications in a rat model.
View Article and Find Full Text PDFWorld J Diabetes
January 2025
Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Background: There is a lack of clinical evidence on the efficacy and safety of transitioning from a thrice-daily pre-mixed insulin or basal-prandial regimen to insulin deglu-dec/aspart (IDegAsp) therapy, with insufficient data from the Chinese popu-lation.
Aim: To demonstrate the efficacy, safety, and treatment satisfaction associated with the transition to IDegAsp in type 2 diabetes mellitus (T2DM).
Methods: In this 12-week open-label, non-randomized, single-center, pilot study, patients with T2DM receiving thrice-daily insulin or intensive insulin treatment were transitioned to twice-daily injections of insulin IDegAsp.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!